Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Opinion|Articles|July 4, 2025
Top 10 Urology Times videos from the first half of 2025
Author(s)Urology Times staff
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Catch up on exclusive videos you may have missed from the first half of the year.
Advertisement
Advertisement
The first half of 2025 generated plenty of headlines in the urology space, ranging from conferences such as the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, American Urological Association 2025 Annual Meeting, and ASCO Annual Meeting. Besides conferences, other key headlines involved the FDA’s approval of perioperative durvalumab (Imfinzi) with neoadjuvant chemotherapy for adult patients with
Related to this article
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Advertisement
Advertisement